Lead Product(s) : Burixafor Hydrobromide,GM CSF,Propranolol Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Exicure Completes Enrollment for GPC-100 Phase 2 Myeloma Transplant Study
Details : GPC-100 (burixafor) is a highly selective small molecule antagonist of CXCR4, being investigated with propranolol and G-CSF in multiple myeloma patients undergoing autologous transplant.
Product Name : GPC-100
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 05, 2025
Lead Product(s) : Burixafor Hydrobromide,GM CSF,Propranolol Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
